vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $13.8M, roughly 1.6× FENNEC PHARMACEUTICALS INC.). BGSF, INC. runs the higher net margin — -5.3% vs -34.7%, a 29.5% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -9.4%). Over the past eight quarters, BGSF, INC.'s revenue compounded faster (-5.3% CAGR vs -26.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BGSF vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $13.8M |
| Net Profit | $-1.2M | $-4.8M |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | -18.5% |
| Net Margin | -5.3% | -34.7% |
| Revenue YoY | -9.4% | 73.8% |
| Net Profit YoY | -18.2% | -141.1% |
| EPS (diluted) | $-0.12 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $13.8M | ||
| Q3 25 | $26.9M | $12.5M | ||
| Q2 25 | $23.5M | $9.7M | ||
| Q1 25 | $20.9M | $8.8M | ||
| Q4 24 | $24.3M | $7.9M | ||
| Q3 24 | $29.8M | $7.0M | ||
| Q2 24 | $25.7M | $7.3M | ||
| Q1 24 | $24.5M | $25.4M |
| Q4 25 | $-1.2M | $-4.8M | ||
| Q3 25 | $-5.8M | $-638.0K | ||
| Q2 25 | $-3.7M | $-3.2M | ||
| Q1 25 | $-722.0K | $-1.2M | ||
| Q4 24 | $-981.0K | $-2.0M | ||
| Q3 24 | $-804.0K | $-5.7M | ||
| Q2 24 | $-761.0K | $-5.6M | ||
| Q1 24 | $-792.0K | $12.8M |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | -18.5% | ||
| Q3 25 | -3.5% | -1.5% | ||
| Q2 25 | -18.8% | -28.3% | ||
| Q1 25 | 1.6% | -9.2% | ||
| Q4 24 | -15.7% | -11.8% | ||
| Q3 24 | -3.4% | -74.6% | ||
| Q2 24 | -5.7% | -69.4% | ||
| Q1 24 | 1.7% | 54.2% |
| Q4 25 | -5.3% | -34.7% | ||
| Q3 25 | -21.6% | -5.1% | ||
| Q2 25 | -15.9% | -32.7% | ||
| Q1 25 | -3.5% | -13.3% | ||
| Q4 24 | -4.0% | -25.0% | ||
| Q3 24 | -2.7% | -82.2% | ||
| Q2 24 | -3.0% | -76.5% | ||
| Q1 24 | -3.2% | 50.6% |
| Q4 25 | $-0.12 | $-0.17 | ||
| Q3 25 | $-0.52 | $-0.02 | ||
| Q2 25 | $-0.34 | $-0.11 | ||
| Q1 25 | $-0.06 | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $-0.07 | $-0.21 | ||
| Q2 24 | $-0.07 | $-0.20 | ||
| Q1 24 | — | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $35.5M |
| Total Assets | $57.8M | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $36.8M | ||
| Q3 25 | $41.2M | $21.9M | ||
| Q2 25 | $2.8M | $18.7M | ||
| Q1 25 | $2.0M | $22.7M | ||
| Q4 24 | $32.0K | $26.6M | ||
| Q3 24 | $262 | $40.3M | ||
| Q2 24 | $226 | $43.1M | ||
| Q1 24 | $50 | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $48.1M | $35.5M | ||
| Q3 25 | $50.7M | $-4.5M | ||
| Q2 25 | $78.3M | $-7.5M | ||
| Q1 25 | $81.8M | $-5.9M | ||
| Q4 24 | $82.3M | $-5.9M | ||
| Q3 24 | $82.9M | $-5.2M | ||
| Q2 24 | $83.2M | $-1.4M | ||
| Q1 24 | $83.6M | $3.0M |
| Q4 25 | $57.8M | $70.6M | ||
| Q3 25 | $83.6M | $49.3M | ||
| Q2 25 | $149.7M | $44.9M | ||
| Q1 25 | $152.3M | $46.4M | ||
| Q4 24 | $150.1M | $44.9M | ||
| Q3 24 | $157.3K | $58.9M | ||
| Q2 24 | $159.8K | $63.2M | ||
| Q1 24 | $170.6K | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-6.0M |
| Free Cash FlowOCF − Capex | $1.7M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-6.0M | ||
| Q3 25 | $-4.8M | $1.5M | ||
| Q2 25 | $2.2M | $-3.7M | ||
| Q1 25 | $1.1M | $-4.3M | ||
| Q4 24 | $3.2M | $-1.5M | ||
| Q3 24 | $6.5M | $-2.2M | ||
| Q2 24 | $7.3M | $-8.4M | ||
| Q1 24 | $7.4M | $39.0M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $6.9M | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 9.1% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 21.7% | — | ||
| Q2 24 | 28.5% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
FENC
Segment breakdown not available.
